Abstract
Prostate cancer is the most common carcinoma among aged males in western countries and more aggressive and lethal castration resistant prostate cancer often occurs after androgen deprivation therapy. The high expression of androgens and androgen receptor is closely related to prostate cancer. Efficient androgen receptor antagonists, such as enzalutamide and ARN-509, could be employed as potent anti-prostate cancer agents. Nevertheless, recent studies have revealed that F876L mutation in androgen receptor converts the action of enzalutamide and ARN-509 from an antagonist to agonist, so that novel strategies are urgent to address this resistance mechanism. In this review, we focus on the discussion about some novel strategies, which targets androgen receptor mainly through the degrading pathway as potential treatments for prostate cancer.
Keywords: Resistance mechanism, androgen receptor, degradation, prostate cancer, small molecules, new strategies.
Current Cancer Drug Targets
Title:Degradation of Androgen Receptor through Small Molecules for Prostate Cancer
Volume: 18 Issue: 7
Author(s): Raoling Ge, Xi Xu, Pengfei Xu, Lei Li, Zhiyu Li*Jinlei Bian*
Affiliation:
- Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009,China
- Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009,China
Keywords: Resistance mechanism, androgen receptor, degradation, prostate cancer, small molecules, new strategies.
Abstract: Prostate cancer is the most common carcinoma among aged males in western countries and more aggressive and lethal castration resistant prostate cancer often occurs after androgen deprivation therapy. The high expression of androgens and androgen receptor is closely related to prostate cancer. Efficient androgen receptor antagonists, such as enzalutamide and ARN-509, could be employed as potent anti-prostate cancer agents. Nevertheless, recent studies have revealed that F876L mutation in androgen receptor converts the action of enzalutamide and ARN-509 from an antagonist to agonist, so that novel strategies are urgent to address this resistance mechanism. In this review, we focus on the discussion about some novel strategies, which targets androgen receptor mainly through the degrading pathway as potential treatments for prostate cancer.
Export Options
About this article
Cite this article as:
Ge Raoling , Xu Xi , Xu Pengfei , Li Lei , Li Zhiyu *, Bian Jinlei *, Degradation of Androgen Receptor through Small Molecules for Prostate Cancer, Current Cancer Drug Targets 2018; 18 (7) . https://dx.doi.org/10.2174/1568009617666171107103936
DOI https://dx.doi.org/10.2174/1568009617666171107103936 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Lycopene in the Control of ROS-Mediated Cell Growth: Implications in Cancer Prevention
Current Medicinal Chemistry Evaluation of the Binding Affinity of a Gonadotropin-Releasing Hormone Analogue (GnRH-a) Buserelin through <i>In silico</i> and <i>In vivo</i> Testing in <i>Clarias magur</i>
Current Proteomics Osteopontin: An Effector and an Effect of Tumor Metastasis
Current Molecular Medicine Nanoparticles based on oleate alginate ester as curcumin delivery system
Current Drug Delivery Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Current Drug Metabolism Non-Invasive Cell Tracking in Cancer and Cancer Therapy
Current Topics in Medicinal Chemistry Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy Design, Synthesis and Biological Evaluation of Novel 1, 3- thiazolidine-2, 4-diones as Anti-prostate Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms
CNS & Neurological Disorders - Drug Targets Prospective Plant Based Anticancer Lead Molecules
Current Topics in Medicinal Chemistry Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients
Drug Metabolism Letters Inhibition of Protein Kinase c-Src as a Therapeutic Approach for Cancer and Bone Metastases
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Editorial
Current Nutrition & Food Science Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery